NFA
SRNE

Nationwide Fund Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Nationwide Fund Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,417
Closed -$57K – 3289
2017
Q1 		$57K Sell
14,417
-2,037
-12% -$10.2K ﹤0.01% 2963
2016
Q4 		$81K Sell
16,454
-1,893
-10% -$11.4K ﹤0.01% 2927
2016
Q3 		$142K Hold
18,347
– – ﹤0.01% 2782
2016
Q2 		$103K Hold
18,347
– – ﹤0.01% 2907
2016
Q1 		$99K Hold
18,347
– – ﹤0.01% 2823
2015
Q4 		$160K Hold
18,347
– – ﹤0.01% 2656
2015
Q3 		$154K Hold
18,347
– – ﹤0.01% 2701
2015
Q2 		$323K Buy
+18,347
New +$236K ﹤0.01% 2478

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nationwide Fund Advisors's SRNE Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2017, closing a stake of 14,417 shares — an estimated $57K sold.

Nationwide Fund Advisors first reported a position in SRNE in Q2 2015 and held it in 8 quarters. The position peaked at $323K in Q2 2015. 46 funds tracked by Wall St. Rank hold SRNE as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 14,417 Sorrento Therapeutics, Inc. shares in Q2 2017, an estimated $57K.
  • Nationwide Fund Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 8 quarters.
  • Nationwide Fund Advisors's Sorrento Therapeutics, Inc. position peaked at $323K in Q2 2015.
  • 46 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.